在晚期胃癌的临床研究中，泰索帝和开普拓（CPT-11）比奥沙利铂、S-1和其他正在进行早期研究的新药显得更有发达前景。
Taxotere and CPT-11 appear to hold more promise in the investigation of patients with AGC than drugs like oxaliplatin, S-1, or many new classes of compounds that are under early investigation.
在晚期胃癌的临床研究中，泰索帝和开普拓（CPT-11）比奥沙利铂、S-1和其他正在进行早期研究的新药显得更有发达前景。
Taxotere and CPT-11 appear to hold more promise in the investigation of patients with AGC than drugs like oxaliplatin, S-1, or many new classes of compounds that are under early investigation.
应用推荐